Novo Nordisk’s $40m wastewater plant to be ‘economic driver’ for US state

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Golfcphoto)
(Image: Getty/Golfcphoto)

Related tags: Diabetes, North carolina, Wastewater treatment, Novo nordisk

Novo Nordisk completes the construction of a wastewater treatment plant in Clayton, North Carolina, which will be donated to the city to aid biopharma growth.

The $40m (€35.8m) wastewater pre-treatment facility was developed through a partnership between North Carolina’s General Assembly, the Golden Leaf Foundation, and Novo Nordisk.

The public-private partnership saw Novo Nordisk pay approximately $30m to develop the facility, while the state provided more than $10m towards its development.

With the facility now completed, Novo Nordisk has donated it to the Clayton Town Council, allowing the town to offer the additional capacity at the plant to potential biopharma companies looking to operate in the area.

In a statement​, the council of Clayton said, “The treatment plant was built to be an economic driver for the entire region, and its modular design will allow tremendous flexibility and expansion capacity for current and future biopharma partners who will be able to plug into the facility as well.”

The plant took four years to construct and is built on an eight-acre site. The facility is able to treat approximately 450,000 gallons of industrial wastewater per day, with further room for expansion.

The treatment center will be able to remove chemicals, such as nitrogen and phosphorus, from water, which could be harmful to aquatic ecosystems.

The wastewater treatment facility was needed due to Novo Nordisk’s expansion in the town; in 2015​, the company announced that it would spend $2bn expanding two facilities across its diabetes portfolio.

In fact, the bulk of this spend was earmarked for its Clayton site, with $1.8bn being used to create an 833,000-square-foot active pharmaceutical ingredient (API) facility for the manufacture of semaglutide, a GLP-1 analogue formulated as a once-daily treatment for type 2 diabetes.

This newly developed site is not yet operational, though it was scheduled to be completed this year; however, the wastewater site will be made immediately available to Novo Nordisk’s new facility.

Related news

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more